Home » Newsletters » BioWorld Science

BioWorld Science

April 13, 2018

View Archived Issues

CTA approval for ARGX-112 triggers milestone payment to Argenx

ImmunoCellular Therapeutics achieves milestone in Stem-to-T-Cell program

Phase I trial of TQB-2450 approved and initiated in China

RubrYc Therapeutics closes series A financing

Adynxx presents promising phase II data from ADYX-004 study of brivoligide

Novel mutation in SMARCE1 gene discovered in OAFNS

Humanetics obtains NIAID grant to support development of BIO-300 as a medical countermeasure

Beijing Tiancheng Pharma divulges new FGFR inhibitors

BMS and Harvard enter fibrosis research collaboration

University of Ottawa, Lcb Pharma patent nucleoside and nucleotide analogues

Patient recruitment ongoing in phase I study of BIIB-095

Novel dopamine beta-hydroxylase inhibitors identified at BIAL-Portela & Ca.

Dinutuximab plus irinotecan well tolerated in part 1 of phase II/III small cell lung cancer study

Emergent BioSolutions completes MRP for BioThrax in five E.U. countries

Deerfield leads investment in Sollis Therapeutics

Galapagos announces plans for phase III program of GLPG-1690 in IPF

New PIEZO1 gene mutations associated with nonimmune hydrops fetalis

STK25 identified as a therapeutic target for NAFLD

FDA finalizes guidance on NGS-based tests

Phase I/II study of DNA vaccine for hypertension begins in Australia

GSK to transfer rare disease gene therapy portfolio to Orchard Therapeutics

PCSK7, a potential therapeutic target for metabolic disorders

FDA approves use of IDx-DR to detect diabetic retinopathy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
European Commission floats multiple fixes for MDR, IVDR
BioWorld MedTech
The European Union’s struggles with regulations for devices and in vitro diagnostics seem virtually endless, but the European Commission floated a series of...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.